Teva Pharmaceutical Industries (TEVA) EBT Margin (2016 - 2025)
Historic EBT Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 6.37%.
- Teva Pharmaceutical Industries' EBT Margin rose 122100.0% to 6.37% in Q4 2025 from the same period last year, while for Dec 2025 it was 8.36%, marking a year-over-year increase of 104800.0%. This contributed to the annual value of 7.09% for FY2025, which is 148500.0% up from last year.
- According to the latest figures from Q4 2025, Teva Pharmaceutical Industries' EBT Margin is 6.37%, which was up 122100.0% from 14.42% recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' EBT Margin registered a high of 14.42% during Q3 2025, and its lowest value of 39.38% during Q4 2023.
- Its 5-year average for EBT Margin is 5.45%, with a median of 1.3% in 2021.
- In the last 5 years, Teva Pharmaceutical Industries' EBT Margin skyrocketed by 1219200bps in 2021 and then plummeted by -389900bps in 2022.
- Over the past 5 years, Teva Pharmaceutical Industries' EBT Margin (Quarter) stood at 4.27% in 2021, then crashed by -615bps to 30.51% in 2022, then fell by -29bps to 39.38% in 2023, then soared by 85bps to 5.84% in 2024, then skyrocketed by 209bps to 6.37% in 2025.
- Its last three reported values are 6.37% in Q4 2025, 14.42% for Q3 2025, and 4.86% during Q2 2025.